Trial Profile

Randomised, Open-label and Parallel Group Trial to Investigate the Effects of Oral BI 685509 Alone or in Combination With Empagliflozin on Portal Hypertension After 8 Weeks Treatment in Patients With Clinically Significant Portal Hypertension (CSPH) in Compensated Cirrhosis

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 01 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avenciguat (Primary) ; Empagliflozin (Primary)
Indications Portal hypertension
Focus Therapeutic Use
Sponsors Boehringer Ingelheim; Boehringer Ingelheim GmbH International; Boehringer Ingelheim Pharma KG

17 Jun 2024 Status changed from active, no longer recruiting to discontinued as per company decision
28 May 2024 Planned End Date changed from 20 Jun 2024 to 7 Jun 2024.
28 May 2024 Planned primary completion date changed from 23 May 2024 to 7 Jun 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com